Agatolimod and Trastuzumab in Treating Patients With Locally Advanced or Metastatic Breast Cancer
Stopped early · Phase 2
Conditions studied: Breast Cancer
In brief
RATIONALE: Biological therapies, such as agatolimod, may stimulate the immune system in different ways and stop tumor cells from growing. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving agatolimod together with trastuzumab may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving agatolimod together with trastuzumab works in treating patients with locally advanced or metastatic breast cancer.
Key facts
- Study ID
- NCT00824733
- Run by
- Bhuvaneswari Ramaswamy
- People needed
- 6
- Starts
- 2009-02-01
- Expected to finish
- 2014-04-01
- Last updated by the study team
- 2016-01-14
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- The Ohio State University Wexner Medical Center — Columbus, Ohio, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.